Skip to content
Open access

Formulation and Evaluation of Apixaban Nanocrystals Using Antisolvent Precipitation Technique for Enhanced Oral Bioavailability

Oct 2026 · Future Journal of Pharmaceuticals and Health Sciences · 0 citations

Abstract

Apixaban is a Biopharmaceutics Classification System (BCS) class II anticoagulant whose clinical performance is limited by poor aqueous solubility and dissolution rate, leading to variable oral absorption. The present study aimed to develop and evaluate apixaban nanocrystals using the antisolvent precipitation technique to enhance its dissolution behavior and oral bioavailability. The optimized formulation was characterized for particle size, polydispersity index, zeta potential, drug content, saturation solubility, Fourier-transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), in vitro dissolution, and stability under accelerated storage conditions. The optimized nanocrystal formulation exhibited a narrow particle size distribution with satisfactory stability and drug content. In vitro dissolution studies demonstrated a markedly faster drug release from the nanocrystal formulation compared with the untreated drug, indicating enhanced dissolution performance. These findings suggest that antisolvent precipitation is a promising and scalable approach for producing apixaban nanocrystals and may improve the oral delivery of poorly water-soluble drugs. Further in vivo pharmacokinetic studies are warranted to confirm the enhancement in oral bioavailability.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.